Glaxosmithkline Share Price | |
---|---|
Price | 1,631.50 |
Bid | 1,631.00 |
Ask | 1,632.00 |
Change | -8.50 (-0.52%) |
Volume | 516,068 |
Open | 1,633.00 |
High | 1,641.00 |
Low | 1,628.00 |
Prev. Close | 1,640.00 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 4.08b |
Market Capitalisation | £66.53b |
Market Size | 1,500 |
52 Week High | 1,820.00 |
52 Week High Date | 15-May-2024 |
52 Week Low | 1,302.60 |
52 Week Low Date | 11-Jul-2023 |
# Trades | 1,444 |
---|---|
Vol. Sold | 300,643 |
Sold Value | £4.91m |
Vol. Bought | 198,716 |
Bought Value | £3.25m |
PE Ratio | 13.41694 |
Earnings | 121.60 |
Dividend | 55.50 |
Yield | 3.402% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
07-Jun-24 | 09:29:57 | 1,631.338 | 1,000 | Buy* | 1,631.00 | 1,631.50 | 16.31k | O Ordinary |
07-Jun-24 | 09:29:26 | 1,631.487 | 222 | Sell* | 1,631.00 | 1,632.00 | 3,622 | O Ordinary |
07-Jun-24 | 09:29:12 | 1,631.50 | 669 | Buy* | 1,631.00 | 1,631.50 | 10.91k | A Automatic Execution |
07-Jun-24 | 09:29:12 | 1,631.50 | 297 | Buy* | 1,631.00 | 1,631.50 | 4,846 | A Automatic Execution |
07-Jun-24 | 09:29:04 | 1,631.50 | 954 | Buy* | 1,631.00 | 1,631.50 | 15.56k | A Automatic Execution |
07-Jun-24 | 09:29:04 | 1,631.50 | 349 | Buy* | 1,631.00 | 1,631.50 | 5,694 | A Automatic Execution |
07-Jun-24 | 09:28:26 | 1,631.00 | 322 | Sell* | 1,631.00 | 1,631.50 | 5,252 | O Ordinary Trade was executed as an SI |
07-Jun-24 | 09:28:21 | 1,631.50 | 116 | Sell* | 1,631.00 | 1,632.00 | 1,893 | A Automatic Execution |
07-Jun-24 | 09:28:21 | 1,631.50 | 82 | Sell* | 1,631.50 | 1,632.00 | 1,338 | A Automatic Execution |
07-Jun-24 | 09:28:21 | 1,631.50 | 118 | Sell* | 1,631.50 | 1,632.00 | 1,925 | A Automatic Execution |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
20-May-24 | 16-May-24 | Buy Dividends | Hal Barron held the position of Non-Executive Director at the time of this trade.Hal Barron | 44.88 | USD | 2,433 | 3,373,198 |
20-May-24 | 16-May-24 | Buy Dividends | Hal Barron held the position of Non-Executive Director at the time of this trade.Hal Barron | 4,488.00 | GBX | 61 | 3,373,198 |
14-May-24 | 10-May-24 | Transfer From | Julie Brown held the position of Chief Finance Officer at the time of this trade.Julie Brown | 0.00 | 7 | 41,995 | |
14-May-24 | 10-May-24 | Buy | Julie Brown held the position of Chief Finance Officer at the time of this trade.Julie Brown | 1,794.34 | GBX | 7 | 41,995 |
14-May-24 | 10-May-24 | Transfer From | Emma Walmsley held the position of CEO at the time of this trade.Emma Walmsley | 0.00 | 7 | 2,190,863 |
At GSK, we unite science, technology and talent to get ahead of disease together